Via News Knowledge File

Sanofi

organization80% conf.·synced Jul 5, 2026

Pharmaceutical company partnered with Teva for duvakitug additional indications

sourced metrics

753

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price

3.0percent_ytd_return

⚠ sources conflictsource

Eps

4.96USD

⚠ sources conflictsource

Margin

-68.7percent

Apr 1, 2026source

Rare Disease Commitment

40years

Feb 2, 2026source

Rare Disease Experience

40years

Feb 2, 2026source

Collaboration Revenue

5.9billion_USD

Jan 30, 2026⚠ sources conflictsource

Acquisition Price Per Share

15.50USD

Dec 24, 2025source

China Approvals 2025

5approvals

Dec 11, 2025source

China Drug Approvals 2025

5approvals

Dec 11, 2025source

Investment Amount

40million_EUR

Nov 1, 2024source

Specific Project Investment

25million_EUR

Nov 1, 2024source

Rd Investment

606million_EUR

Mar 31, 2024source

Dashboard Count

3unified_dashboards

Jan 1, 2024source

Stated objectives

Advance Dynavax's shingles vaccine candidate (Z-1018) through clinical development

source

stated

Augment Sanofi's presence in adult immunization by combining Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach

source

stated

Provide vaccine protection across the lifespan through differentiated vaccine portfolio

source

stated

Submit global regulatory submissions for amlitelimab

source

stated

Report results from AQUA and ESTUARY phase 3 studies

source

stated

Study dupilumab in chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis in phase 3 studies

source

stated

Complete global regulatory submissions for amlitelimab

source

stated

Publish results from AQUA and ESTUARY phase 3 studies

source

stated

Present COAST 1, COAST 2, SHORE and ATLANTIS results at upcoming medical conferences

source

stated

Study dupilumab in phase 3 trials for chronic pruritus of unknown origin, chronic lichen simplex, and allergic fungal rhinosinusitis

source

stated

Relationship graph · 753 connections

Employs

219

Developed by

130

regulates

Competes with

headquartered in

regulated by

researched at

Owns

Via News coverage

Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies

February 18, 2026

GSK's Six-Monthly Asthma Biologic Could Reshape Treatment Standards From London to Lagos

February 18, 2026

Kinross Gold And 4 Other Stocks Have Very High Payout Ratio

May 20, 2024

Canopy Growth And Technical Communications Corporation On The List Of Winners And Losers Of Wednesday's US Session

March 27, 2024

Canaan And Signet Jewelers Limited On The List Of Winners And Losers Of Wednesday's US Session

March 20, 2024

Teva Pharmaceutical Already 4% Up, Almost One Hour Before The Market Open

February 26, 2024

Sangamo Therapeutics And FibroGen On The List Of Winners And Losers Of Tuesday's US Session

February 20, 2024

Agenus And Fastly On The List Of Winners And Losers Of Thursday's US Session

February 15, 2024

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →